Comment on ‘Clinical Significance of BRAF Non-V600e Mutations on the Therapeutic Effects of Anti-Egfr Monoclonal Antibody Treatment in Patients With Pretreated Metastatic Colorectal Cancer: The Biomarker Research for Anti-Egfr Monoclonal Antibodies by Comprehensive Cancer Genomics (BREAC) Study’

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0012-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC